Skip to Content
Search Menu

ESMO 2025: Darolutamide-Treated mHSPC Patients Show a More Durable and Stronger PSA Response vs Abiraterone 

Interview: Real-world data presented at ESMO 2025 indicate that darolutamide may deliver deeper and more durable PSA responses in mHSPC compared with abiraterone. Dr. Alicia Morgans discusses the implications for patient outcomes.

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Related

ESMO 2025: Advancements to improve patient outcomes and quality of life in Immunotherapy

/ Christina Ruhlmann
ESMO25 Play the Video 4:45

ESMO 2025: De-Escalated Chemotherapy Prior to Maintenance Avelumab Is Effective in Advanced Urothelial Cancer

/ Enrique Grande
Bladder cancerESMO25 Play the Video 04:57

ESMO 2025: Adjuvant Cemiplimab Improves Outcomes in High-Risk Cutaneous SCC

/ Danny Rischin
ESMO25Skin cancer Play the Video 03:46

ESMO 2025: The Future of Oncology Will Be Built by Individuals

/ Jan Andreasen
ESMO25

ESMO 2025: Treatment with CDK4/6 Inhibitors Extending Their Benefit and Reinforcing the Value for Patients with High-Risk HR+, HER2-Negative Early Breast Cancer

/ Jan Andreasen
Breast cancerESMO25

ESMO 2025: A Potential New Anthracycline-Free Neoadjuvant Regimen for Patients with High-Risk HER2-Positive Early Breast Cancer

/ Jan Andreasen
Breast cancerESMO25
Neeraj Agarwal

Talazoparib and Enzalutamide: A Game-Changer for mCRPC

/ Neeraj Agarwal
ASCOGU25Prostate cancer Play the Video 18:34

Bone Pain as a Key Prognostic Indicator in Castration-Sensitive Prostate Cancer

/ Deniz Tural / Jan Andreasen
ASCOGU25Prostate cancer
Nick James

Oestrogen Reimagined: A Breakthrough Approach for Metastatic Prostate Cancer

/ Nick James
ASCOGU25Prostate cancer Play the Video 09:06
Back to top